Amgen Inc. ($AMGN) Stock Forecast: Up 6.1% Today

What is Amgen Inc.?

Amgen Inc. (AMGN) is a biotechnology company with a strong presence in therapeutic areas such as cardiovascular, oncology, and rare diseases, known for its innovative products. The company recently posted robust quarterly earnings and is concentrating on expanding its product portfolio.

Why is Amgen Inc. going up?

AMGN stock is up 6.1% on Feb 5, 2026 14:43

• Today's positive movement in Amgen's stock could be a result of favorable investor sentiment following its strong quarterly earnings and increased dividend payout, indicating confidence in its product pipeline.
• The announcement of a SPAC merger by stem cell specialist PrimeGen US may have contributed to a positive market sentiment towards biotech firms, including Amgen, as non-traditional paths to public markets gain attention.
• Despite a maintained Underperform rating by Bank of America, referencing a shifted trial timeline for Amgen, the market appears more focused on the company's strong financial performance and growth prospects, overshadowing immediate concerns.
• Amgen's focus on diverse growth drivers, investments in research and development, and disciplined capital allocation during its recent earnings call likely reassured investors about the company's long-term potential for value creation, driving the positive movement.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Stem Cell Specialist PrimeGen Takes SPAC Track to Nasdaq

PrimeGen US, a stem cell specialist, is going public via a Special Purpose Acquisition Company (SPAC) merger with DT Cloud Star Acquisition Corporation. The deal values PrimeGen at $1.5 billion and will fund its preclinical pipeline of triple-activated mesenchymal stem cells for acute liver injury. This move highlights SPACs as an alternative route to the public market for biotechs, especially those yet to enter clinical trials.

https://www.biospace.com/business/stem-cell-specialist-primegen-takes-spac-track-to-nasdaq

Amgen Inc. $AMGN Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. reduced its stake in Amgen Inc. by 13.5% during the third quarter, selling over 200,000 shares. Despite this, other institutional investors increased their holdings, and the company recently reported strong quarterly earnings, beating analyst estimates for EPS and revenue. Amgen also increased its quarterly dividend and received several positive analyst price target revisions, reflecting confidence in its product pipeline, particularly in obesity assets.

https://www.marketbeat.com/instant-alerts/filing-amgen-inc-amgn-shares-sold-by-envestnet-asset-management-inc-2026-02-05/

Bank of America Maintains Underperform on Amgen Inc (AMGN) Feb 2026

Bank of America Securities maintained an Underperform rating on Amgen Inc. (AMGN) on February 4, 2026, primarily due to a shifted timeline for the pelacarsen trial readthrough to mid-2026. This move suggests BofA anticipates Amgen will underperform the market or its peers in the near term, a view that coincided with a 7.64% drop in Amgen's share price since the note was published. The rating did not include a new price target, emphasizing the impact of catalyst timing on investor sentiment rather than a change in long-term fundamentals.

https://meyka.com/blog/bank-of-america-maintains-underperform-on-amgen-inc-amgn-feb-2026-0502/

Amgen Earnings Call: Broad Growth Amid Manageable Risks

Amgen's latest earnings call highlighted broad commercial momentum in 2025 across multiple franchises, including cardiovascular, bone health, oncology, and rare diseases, resulting in double-digit revenue and earnings growth. The company reported strong 2025 financials with 10% sales growth and $8.1 billion in free cash flow, setting confident 2026 targets. While acknowledging regulatory setbacks, clinical uncertainties, and upcoming competitive pressures from biosimilars, Amgen emphasized its diversified growth drivers, robust R&D investment, and disciplined capital allocation as factors outweighing the identifiable risks, positioning it for sustained long-term value creation.

https://www.tipranks.com/news/company-announcements/amgen-earnings-call-broad-growth-amid-manageable-risks

Earnings call transcript: Alphabet Q4 2025 highlights strong earnings beat

Alphabet Inc. (GOOG) delivered strong financial results for Q4 2025, beating analyst expectations with an EPS of $2.82 and revenue of $113.8 billion. The company saw an 18% increase in revenue year-over-year, surpassed $400 billion in annual revenue for the first time, and plans significant AI investments with anticipated 2026 CapEx between $175 billion-$185 billion. Key growth drivers included advancements in AI, increased demand for enterprise AI solutions, strong performance in Search, YouTube subscriptions, and Google Cloud, with the stock rising 0.97% in after-hours trading.

https://www.investing.com/news/transcripts/earnings-call-transcript-alphabet-q4-2025-highlights-strong-earnings-beat-93CH-4486264

Trending Today

Bittensor ($TAO) Crypto Forecast: Down 5.2% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.2% Today

Under Armour Inc. Class A ($UAA) Stock Forecast: Up 5.0% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Up 5.2% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.8% Today

Unity Software ($U) Stock Forecast: Up 6.5% Today

Amphenol Corporation ($APH) Stock Forecast: Up 5.4% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

MicroStrategy ($MSTR) Stock Forecast: Up 8.6% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.0% Today

Amgen Inc. Price History

05.10.2025 - AMGN Stock was up 5.3%

• Q3 earnings and revenues for Amgen (AMGN) surpassed expectations, indicating strong financial performance and potentially positive future outlook.
• Despite a slight decline in the current session, the stock has demonstrated resilience over the past month and year, suggesting a reliable long-term investment opportunity.
• Investors are closely monitoring Amgen's Q3 results, particularly focusing on the impact of newer drugs, biosimilar competition, and pricing pressures on the company's growth trajectory.
• The optimistic sentiment surrounding Amgen's financial performance and strategic positioning likely played a role in the bullish movement in the stock today.

05.10.2025 - AMGN Stock was up 7.7%

• Amgen's strong bullish movement today can be attributed to its impressive Q3 earnings and sales beat, surpassing estimates and showcasing double-digit growth driven by key drugs.
• The company's decision to raise its 2025 outlook has instilled confidence in investors, leading to a positive market response.
• Investors are likely encouraged by the company's ability to consistently outperform expectations, as seen in the significant earnings and revenue surprises for the quarter.
• The market's positive reaction also reflects investors' anticipation of Amgen's future performance, as they delve deeper into the company's potential beyond just headline estimates.

07.00.2026 - AMGN Stock was up 5.0%

• Amgen's acquisition of Dark Blue Therapeutics for $840 million, aimed at expanding its oncology pipeline, has instilled optimism among investors regarding the company's strategic growth plans.
• The raise in Amgen's dividend to $2.52 indicates a sustainable payout ratio and a robust earnings growth projection, appealing to income-focused investors and contributing to the stock's performance.
• Comparatively, while Regeneron Pharmaceuticals has had quieter institutional appeal, Amgen's proactive stance in bolstering its portfolio and market standing has garnered positive attention.
• The general bullish outlook on Amgen is also influenced by the optimistic prospects within the broader biotech sector, where investors are acknowledging the potential driven by innovative treatments and strategic acquisitions for future growth.

05.00.2026 - AMGN Stock was down 1.4%

• The decline in Amgen's stock today may be linked to AbbVie's entry into the lung cancer drug market, potentially posing a competitive challenge for Amgen and affecting investor sentiment.
• Despite Amgen's positive quarterly earnings and dividend increase, market reaction might be influenced by the uncertainty surrounding the impact of AbbVie's new drug.
• Sizeable investments from D.A. Davidson & CO., Greenspring Advisors LLC, and Railway Pension Investments Ltd. indicate confidence in Amgen's future outlook. However, market caution could be attributed to the competitive landscape in lung cancer treatments.
• Overall, market sentiment towards Amgen remains optimistic, evident from analyst ratings and price targets. However, today's bearish trend suggests that investors are attentive to evolving competition within the biopharmaceutical sector.

04.01.2026 - AMGN Stock was up 4.3%

• Impressive annual product sales and a dispute with the FDA over Tavneos did not deter investors, as the stock soared to new heights.
• The company's wide economic moat, driven by its innovative drugs in cardiology and immunology, supported the bullish movement.
• Strong financial results for Q4 2025 and the full year, exceeding earnings expectations, along with an optimistic outlook for 2026, fueled investor confidence in Amgen's future growth potential.
• The market's positive reaction to Amgen's performance could also be attributed to the overall bullish sentiment in the biotechnology sector, as evidenced by Ayrmid's breakthrough in stem cell mobilization for gene therapies.

05.01.2026 - AMGN Stock was up 6.1%

• Today's positive movement in Amgen's stock could be a result of favorable investor sentiment following its strong quarterly earnings and increased dividend payout, indicating confidence in its product pipeline.
• The announcement of a SPAC merger by stem cell specialist PrimeGen US may have contributed to a positive market sentiment towards biotech firms, including Amgen, as non-traditional paths to public markets gain attention.
• Despite a maintained Underperform rating by Bank of America, referencing a shifted trial timeline for Amgen, the market appears more focused on the company's strong financial performance and growth prospects, overshadowing immediate concerns.
• Amgen's focus on diverse growth drivers, investments in research and development, and disciplined capital allocation during its recent earnings call likely reassured investors about the company's long-term potential for value creation, driving the positive movement.

06.07.2025 - AMGN Stock was down 5.1%

• Despite surpassing earnings and revenue projections in the second quarter, the stock displayed downward movement.
• The market's reaction may be linked to concerns about the company's future growth potential despite the positive outcomes.
• Investors appear to be capitalizing on gains following a period of robust performance, causing a temporary decline in the stock value.
• Various broader market dynamics such as sector shifts or general market sentiment could be influencing Amgen's stock price negatively.

06.07.2025 - AMGN Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue projections, Amgen (AMGN) faced a downturn in the market today.
• The market's reaction could be attributed to concerns regarding the company's future growth trajectory or provided guidance.
• Investors may have had higher expectations, prompting profit-taking and a temporary decline in the stock value.
• It is crucial to observe how Amgen addresses any potential underlying issues to determine the continuity of this bearish trend or whether it signals a buying opportunity for investors.

06.00.2026 - AMGN Stock was up 2.3%

• AMGN's bullish movement can be attributed to its strategic acquisition of Dark Blue Therapeutics, a UK-based cancer drug developer, in a deal worth up to $840 million. This acquisition expands AMGN's oncology portfolio and strengthens its position in the biotechnology industry.
• The acquisition of Dark Blue Therapeutics adds an investigational small molecule targeting specific types of acute myeloid leukemia (AML) to AMGN's pipeline, showcasing the company's commitment to advancing oncology therapeutics.
• The market likely responded positively to the news as the acquisition aligns with AMGN's research focus on targeted protein degradation and leukemia therapeutics, demonstrating its dedication to enhancing its early oncology discovery efforts.
• Additionally, the promising preclinical data on the anti-cancer activity of the MLLT1/3 protein degrader acquired through this deal further fueled investor optimism in AMGN's future growth prospects in the oncology space.

04.01.2026 - AMGN Stock was up 7.4%

• Amgen's bullish movement can be attributed to its impressive Q4 2025 earnings report, exceeding expectations with robust growth across its portfolio and optimistic outlook for 2026.
• The company's refusal to pull the rare disease drug Tavneos from the market, despite FDA concerns, showcases Amgen's confidence in the drug's effectiveness and benefit-risk profile, potentially boosting investor confidence.
• Analysts raising price targets for Amgen indicate continued growth potential, supported by its diversified portfolio and focus on cardiovascular treatments.
• The overall positive sentiment towards Amgen, combined with its strategic growth initiatives and strong financial performance, likely contributed to the stock's bullish movement today.

04.01.2026 - AMGN Stock was up 6.9%

• Amgen's upward trend today is influenced by various factors:
• Analysts have a favorable view of the stock, as evidenced by a higher price target set by Royal Bank of Canada and strong Q4 earnings that surpassed predictions.
• The company's focus on cardiovascular treatments and groundbreaking drugs like Repatha has been instrumental in sustaining free cash flow and fostering growth opportunities.
• Despite a disagreement with the FDA regarding the inflammatory drug Tavneos, Amgen's substantial annual product sales demonstrate its resilience in the industry.
• Amgen's optimistic prospects are further supported by its broad economic moat and strategic position in critical therapeutic areas.

01.09.2025 - AMGN Stock was up 5.3%

• A noteworthy expansion of $650 million was unveiled by Amgen for its U.S. manufacturing network, reflecting a bolstered confidence in future growth prospects.
• The stock's bullish trend may be attributed to investors' optimism towards Amgen's strategic decision to enhance manufacturing capacity in response to evolving pharmaceutical tariff policies.
• Notwithstanding a minor market downturn, Amgen's proactive measures to reinforce manufacturing capabilities likely instilled confidence among investors, driving the stock's positive performance.